Abstract:Background Pre-mRNA processing factor 40 homolog A (PRPF40A) is an important protein involved in pre-mRNA splicing and is expressed in a variety of cell types. However, the function of PRPF40A in pancreatic cancer remains unclear. Therefore, our study is to investigate the role of PRPF40A in the pathogenesis of pancreatic cancer. Materials and methods We extracted expression data and clinical information of PRPF40A from different online databases, including the Cancer Genome Atlas (TCGA), Oncomine and the Gene Expression Omnibus (GEO). Subsequently, samples were collected from patients to validate gene expression using qPCR, Western blotting and immunohistochemical (IHC) analyses. Receiver operating characteristic (ROC) and Kaplan-Meier curve were used to evaluate the diagnostic and prognostic potential. Colony formation assays and CCK-8 assays were performed to measure the proliferative capacity of pancreatic cancer. Finally, gene ontology (GO) and pathway enrichment analyses of co-expressed genes of PRPF40A were conducted using the Database for Annotation, Visualization and Integrated Discovery (DAVID). Results We found that PRPF40A was upregulated based on data from both the online databases and our samples. PRPF40A possessed a significant diagnostic value, and its overexpression was associated with poor prognosis. PRPF40A knockdown inhibited cell proliferation in pancreatic cancer. GO and pathway analysis showed that the co-expressed genes were mainly involved in viral processing, mRNA splicing and the AMPK signaling pathway. Conclusion The results suggest that PRPF40A is an oncogene and can serve as a diagnostic and prognostic biomarker for pancreatic cancer. However, the underlying mechanisms remain to be elucidated.

Targeting PRAS40: a novel therapeutic strategy for human diseases

PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways

Expression of Proline-Rich Akt-substrate PRAS40 in Cell Survival Pathway and Carcinogenesis

Pras40 Alleviates Neurotoxic Prion Peptide-Induced Apoptosis Via Mtor-Akt Signaling

An Artificial Protein Modulator Reprogramming Neuronal Protein Functions

[Study of Interaction Between PRAS40 and 14-3-3 Proteins by Using Yeast Two-Hybrid System].

The Molecular Landscape and Biological Alterations Induced by PRAS40-Knockout in Head and Neck Squamous Cell Carcinoma

[Preparation and Detection of Phosphorylated PRAS40 (ser183) Polyclonal Antibody].

PRAS40 Promotes NF-κB Transcriptional Activity Through Association with P65

Bioprotacs Establish RAS As a Degradable Target and Provide Novel RAS Biology Insights

PRPF40A As a Potential Diagnostic and Prognostic Marker is Upregulated in Pancreatic Cancer Tissues and Cell Lines: an Integrated Bioinformatics Data Analysis

Towards the Targeted Protein Degradation of PRMT1

PRMT1 in human neoplasm: cancer biology and potential therapeutic target

Insulin-like Growth Factor-1 Induces the Phosphorylation of PRAS40 Via the PI3K/Akt Signaling Pathway in PC12 Cells.

Targeting RAS Phosphorylation in Cancer Therapy: Mechanisms and Modulators

Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.

Effect of PI3K/Akt Signaling Pathway on PRAS40Thr246 Phosphorylation in Gastric Cancer Cells

Overexpression of PRDM16 attenuates acute kidney injury progression: genetic and pharmacological approaches

Progress in RAS-targeted Therapeutic Strategies: from Small Molecule Inhibitors to Proteolysis Targeting Chimeras.

Can proline dehydrogenase—a key enzyme involved in proline metabolism—be a novel target for cancer therapy?

The essential role of PRAK in tumor metastasis and its therapeutic potential